Conference Coverage: American Association for the Study of Liver Disease (AASLD): The Liver Meeting

Conference Coverage

Nivolumab may extend survival in HCC patients

WASHINGTON – About 20% of patients achieved an objective remission that included complete responses in all subgroups of patients.

Pages